SCHEMBL3017692

SCHEMBL3017692

COc1ccc(S(=O)(=O)N2CCN(c3nc(-c4cc(F)cc(Cl)c4)cs3)CC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.68
HSD17B10 Q99714 3/20 0.68
USP2 O75604 2/20 0.68
RECQL P46063 1/20 0.68
SMN1; SMN2 Q16637 6/20 0.62
ALDH1A1 P00352 6/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
POLB P06746 2/20 0.55
MAPK1 P28482 4/20 0.50
KMT2A Q03164 3/20 0.48
RAB9A P51151 4/20 0.47
NPC1 O15118 2/20 0.47
MMP1 P03956 1/20 0.47
MMP3 P08254 1/20 0.47
MMP7 P09237 1/20 0.47
MMP9 P14780 1/20 0.47
LMNA P02545 5/20 0.47
TSHR P16473 1/20 0.47
PKM P14618 2/20 0.46
PKLR P30613 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010697 0.93 MAPT (0.66) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3013814 0.93 MAPT (0.74) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3010203 0.90 SMN1; SMN2 (0.69) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3002931 0.90 SMN1; SMN2 (0.76) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3010845 0.90 ALDH1A1 (0.66) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3006213 0.89 ALDH1A1 (0.60) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3017992 0.89 MAPT (0.59) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3125836 0.88 MAPT (0.69) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3012953 0.88 SMN1; SMN2 (0.66) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3006781 0.88 MAPT (0.57) MAPTHSD17B10USP2RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.